PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
UnitedHealthcare (UHC) Community Plan’s August policy update revised several medical policies to reflect phase 2 of the DEX® Z-Code requirement for certain molecular diagnostic test services on facility and professional claims.
A DEX® Z-Code is a unique identifier that indicates the test being performed on a claim and allows payers to know exactly what service was rendered. The UHC policy will require the submission of a Z-Code obtained from the DEX® Diagnostics Exchange Registry for claims to be considered for reimbursement.
Included in phase 2 of this policy are venous thromboembolism risk and hereditary thrombophilia testing; diagnosis and high-risk inherited cancer panel; and new Current Procedural Terminology (CPT) and Proprietary Laboratory Analyses (PLA) codes relevant to the scope of services announced.
New PLA codes include 0648U, 0650U, 0651U, 0652U, and several sequencing codes. A complete list of affected medical policies and their applicable code changes is available on the UHC website.
These updates were effective Aug. 1, 2026.
Sources:
https://www.dexzcodes.com/dex/did/i9szsoroou?cat=dex-commercial-plans
https://www.dexzcodes.com/dex/did/t7suingo3s?cat=dex-commercial-plans
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).
The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...